Literature DB >> 25595555

Are RNAi and miRNA therapeutics truly dead?

João Conde1, Natalie Artzi2.   

Abstract

Only a few years ago pharmaceutical companies were excited about the potential of RNA interference (RNAi). Now, financial volatility and subsequent dissolutions of in-house facilities by pharmaceutical companies have had media channels pronouncing that RNAi therapeutics are dead. However, advances in nanomedicine may now help the vast potential of RNAi therapeutics to be fulfilled.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Keywords:  RNAi; biomaterials; delivery vehicle; nanotechnology; pharmaceutical companies

Mesh：

Substances：

Year:  2015        PMID： 25595555     DOI： 10.1016/j.tibtech.2014.12.005

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN： 0167-7799            Impact factor:   19.536


  20 in total

Review 1.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

Review 2.  MicroRNAs in glaucoma and neurodegenerative diseases.

Authors:  Milena Molasy; Anna Walczak; Jerzy Szaflik; Jacek P Szaflik; Ireneusz Majsterek
Journal:  J Hum Genet       Date:  2016-07-14       Impact factor: 3.172

3.  The effector mechanism of siRNA spherical nucleic acids.

Authors:  Gokay Yamankurt; Robert J Stawicki; Diana M Posadas; Joseph Q Nguyen; Richard W Carthew; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-03       Impact factor: 11.205

Review 4.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

5.  MiR181c inhibits ovarian cancer metastasis and progression by targeting PRKCD expression.

Authors:  Lijuan Yao; Li Wang; Fengxia Li; Xihai Gao; Xuegong Wei; Zhihui Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 6.  Promise of chemokine network-targeted nanoparticles in combination nucleic acid therapies of metastatic cancer.

Authors:  Ying Xie; Yazhe Wang; Jing Li; Yu Hang; David Oupický
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 7.  Oral nucleic acid therapy using multicompartmental delivery systems.

Authors:  Husain Attarwala; Murui Han; Jonghan Kim; Mansoor Amiji
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-05-24

Review 8.  Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Authors:  Philipp M Cromm; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-06-22       Impact factor: 8.116

9.  Hyaluronate-coated perfluoroalkyl polyamine prodrugs as bioactive siRNA delivery systems for the treatment of peritoneal cancers.

Authors:  Ao Yu; Siyuan Tang; Ling Ding; Jackson Foley; Weimin Tang; Huizhen Jia; Sudipta Panja; Cassandra E Holbert; Yu Hang; Tracy Murray Stewart; Lynette M Smith; Diptesh Sil; Robert A Casero; David Oupický
Journal:  Biomater Adv       Date:  2022-03-17

Review 10.  Ki67 targeted strategies for cancer therapy.

Authors:  C Yang; J Zhang; M Ding; K Xu; L Li; L Mao; J Zheng
Journal:  Clin Transl Oncol       Date:  2017-10-20       Impact factor: 3.340
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.